AT
TARS icon

Arlington Trust’s Tarsus Pharmaceuticals TARS Stock Holding History

Arlington Trust’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76K Hold
28
– – ﹤0.01% 685
2026
Q1 		$1.96K Buy
+28
New +$1.96K ﹤0.01% 647

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Arlington Trust's TARS Position: Q2 2026 in Review

Arlington Trust held its Tarsus Pharmaceuticals (TARS) position steady in Q2 2026 at 28 shares worth $1.76K. The position accounts for ﹤0.01% of the portfolio, ranked #685.

Arlington Trust first reported a position in TARS in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.96K in Q1 2026. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Arlington Trust held 28 shares of Tarsus Pharmaceuticals worth $1.76K as of Q2 2026.
  • Arlington Trust left its Tarsus Pharmaceuticals share count unchanged in Q2 2026.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Arlington Trust's portfolio in Q2 2026, its #685 holding.
  • Arlington Trust first reported a position in Tarsus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Arlington Trust's Tarsus Pharmaceuticals position peaked at $1.96K in Q1 2026.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Arlington Trust's 13F filing for Q2 2026, filed 7 Jul 2026.